XENE (Xenon Pharmaceuticals Inc) Stock Analysis

Xenon Pharmaceuticals Inc (XENE) is a publicly traded Healthcare sector company. As of May 20, 2026, XENE trades at $54.67 with a market cap of $5.19B and a P/E ratio of -12.52. XENE moved +1.17% today. Year to date, XENE is +21.49%; over the trailing twelve months it is +74.64%. Its 52-week range spans $26.74 to $63.95. Analyst consensus is strong buy with an average price target of $78.37. Rallies surfaces XENE's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.

What is the latest XENE stock research?

Xenon Pharmaceuticals Inc (XENE) research on Rallies includes live charts, financials, analyst ratings, hedge fund holdings, politician trades, insider activity, news, AI research, and community context. XENE moved +1.17% today. Analyst consensus is strong buy.

XENE Key Metrics

Key financial metrics for XENE
MetricValue
Price$54.67
Market Cap$5.19B
P/E Ratio-12.52
EPS$-4.36
Dividend Yield0.00%
52-Week High$63.95
52-Week Low$26.74
Volume860.40K
Avg Volume0
Revenue (TTM)$7.50M
Net Income$-345.91M
Gross Margin0.00%

Latest XENE News

Recent XENE Insider Trades

  • KENNEY CHRISTOPHER JOHN sold 1.41K (~$77.87K) on Mar 13, 2026.
  • DiFabio Andrea sold 1.34K (~$74.11K) on Mar 13, 2026.
  • MORTIMER IAN sold 7.31K (~$403.58K) on Mar 13, 2026.

XENE Analyst Consensus

19 analysts cover XENE: 0 strong buy, 19 buy, 0 hold, 0 sell, 0 strong sell. Consensus rating is strong buy. Average price target: $78.37.

Common questions about XENE

What can I research for XENE on Rallies?
Xenon Pharmaceuticals Inc (XENE) research on Rallies includes live charts, financials, analyst ratings, hedge fund holdings, politician trades, insider activity, news, AI research, and community context. XENE moved +1.17% today. Analyst consensus is strong buy.
Does Rallies show live market data for XENE?
Rallies combines live market context with ticker research for XENE, including charts, news, financials, analyst data, institutional holdings, politician trades, insider activity, and AI research where available.
XENE

XENE